Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.87 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307056 | 1.00 | P2RX7 (0.87) | P2RX7NTRK1CTSDCSF1RPDGFRB | |
| SCHEMBL306929 | 0.93 | P2RX7 (1.00) | P2RX7NTRK1CSF1RPDGFRBPDGFRA | |
| SCHEMBL306312 | 0.93 | P2RX7 (1.00) | P2RX7NTRK1CSF1RPDGFRBPDGFRA | |
| SCHEMBL308160 | 0.93 | P2RX7 (1.00) | P2RX7NTRK1CSF1RPDGFRBPDGFRA | |
| SCHEMBL307164 | 0.91 | P2RX7 (0.73) | P2RX7NTRK1CTSD | |
| SCHEMBL307645 | 0.91 | P2RX7 (0.73) | P2RX7NTRK1CTSD | |
| SCHEMBL17690528 | 0.91 | P2RX7 (0.73) | P2RX7NTRK1CTSDCSF1RPDGFRB | |
| SCHEMBL14407705 | 0.86 | P2RX7 (0.76) | P2RX7NTRK1 | |
| SCHEMBL308141 | 0.86 | P2RX7 (0.76) | P2RX7NTRK1 | |
| SCHEMBL12702904 | 0.86 | P2RX7 (0.87) | P2RX7NTRK1CSF1RPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093265-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885NTRK1 2309/4885CTSD 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.